40.61
1.36 (3.46%)
| Previous Close | 39.25 |
| Open | 39.35 |
| Volume | 742,558 |
| Avg. Volume (3M) | 735,520 |
| Market Cap | 2,359,501,824 |
| Price / Earnings (TTM) | 3.60 |
| Price / Sales | 53.92 |
| Price / Book | 1.60 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | 1,798.26% |
| Operating Margin (TTM) | -1,221.97% |
| Diluted EPS (TTM) | 11.54 |
| Quarterly Revenue Growth (YOY) | 6.60% |
| Total Debt/Equity (MRQ) | 3.61% |
| Current Ratio (MRQ) | 18.50 |
| Operating Cash Flow (TTM) | -401.46 M |
| Levered Free Cash Flow (TTM) | -237.66 M |
| Return on Assets (TTM) | -22.88% |
| Return on Equity (TTM) | 60.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Agios Pharmaceuticals, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | -3.0 |
| Price Volatility | 1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.70 |
|
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.65% |
| % Held by Institutions | 101.39% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 65.00 (Scotiabank, 60.06%) | Buy |
| Median | 56.00 (37.90%) | |
| Low | 51.00 (B of A Securities, 25.59%) | Buy |
| Average | 57.33 (41.17%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 39.16 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 04 Sep 2025 | 56.00 (37.90%) | Buy | 40.61 |
| Scotiabank | 28 Jul 2025 | 65.00 (60.06%) | Buy | 37.20 |
| B of A Securities | 22 Jul 2025 | 51.00 (25.58%) | Buy | 39.66 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| SCADDEN DAVID | - | 39.27 | -200 | -7,854 |
| Aggregate Net Quantity | -200 | |||
| Aggregate Net Value ($) | -7,854 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 39.27 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SCADDEN DAVID | Director | 27 Aug 2025 | Automatic sell (-) | 200 | 39.27 | 7,854 |
| SCADDEN DAVID | Director | 27 Aug 2025 | Option execute | 200 | - | - |
| Date | Type | Details |
|---|---|---|
| 04 Sep 2025 | Announcement | Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia |
| 04 Aug 2025 | Announcement | Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia |
| 31 Jul 2025 | Announcement | Agios Reports Second Quarter 2025 Financial Results and Provides Business Update |
| 14 Jul 2025 | Announcement | Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET |
| 08 Jul 2025 | Announcement | Agios Appoints Dr. Jay Backstrom to Board of Directors |
| 09 Jun 2025 | Announcement | Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |